Etanercept (Enbrel)

DRUG9 trials

Conditions

Acute Graft Versus Host DiseaseAnkylosing SpondylitisArthritis, PsoriaticGraft vs Host DiseaseHIV InfectionHealthyInflammationPolymyalgia Rheumatica

Phase 1

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

CompletedNCT00091741

Georgetown UniversityHIV Infection

End: 2004-10-31Target: 10Updated: 2009-07-22

Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects

CompletedNCT01431404

Hanwha ChemicalHealthy

Start: 2011-08-31End: 2013-06-30Updated: 2013-07-08

Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers

CompletedNCT01894412

Hanwha ChemicalHealthy

Start: 2013-07-31End: 2015-12-31Updated: 2016-07-14

Phase 2

Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction

CompletedNCT00006070

National Institute of Dental and Craniofacial Research (NIDCR)Healthy, Inflammation

Start: 2000-07-31End: 2004-05-31Target: 86Updated: 2008-03-04

Phase 3

Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

CompletedNCT00524381

Bispebjerg HospitalPolymyalgia Rheumatica

Start: 2007-08-31End: 2009-09-30Target: 40Updated: 2010-02-23

The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

CompletedNCT00726375

University of Michigan Rogel Cancer CenterAcute Graft Versus Host Disease

Start: 2008-05-31End: 2014-09-30Updated: 2016-01-05

Phase 4

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

CompletedNCT00420238

Wyeth is now a wholly owned subsidiary of PfizerAnkylosing Spondylitis

Start: 2007-01-31End: 2009-05-31Updated: 2010-06-29

Unknown Phase

Study Evaluating the Safety of Enbrel (Etanercept)

CompletedNCT00683384

Wyeth is now a wholly owned subsidiary of PfizerArthritis, Psoriatic

Start: 2007-01-31End: 2009-10-31Updated: 2010-11-16

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

RecruitingNCT07184853

First Affiliated Hospital of Zhejiang UniversityGraft vs Host Disease

Start: 2025-09-25End: 2028-09-25Target: 122Updated: 2025-09-22

Related Papers

Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation2014-06-0224 citations

Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment.

2012-08-159 citations

Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.

2010-09-2061 citations